Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Program Objectives

Rotterdam Study 1990-1999

Burden of Atrial Fibrillation

Efficacy vs Safety NOAC 4-trial Meta-analysis Full Dose

Anticoagulation in Europe in the EORP Registry

Patient Comorbidities at Baseline by Type of Anticoagulant Received

Adequacy of INR Control

When Not to Use NOACs

Rationale for a "Registry"

Mean CHA2DS2-VASc and HAS-BLED Scores According to OAC Treatment

Distribution of OAC Treatment Among New Users With AF from 2011 to 2014

HAS-BLED Bleeding Risk Score

Anticoagulation in Europe: EORP Registry

Recommendations for Prevention of TE in NVAF: NOACs

NOAC Dose Reduction

Antiplatelet Treatment in the ESC Guidelines

NOAC Dose Reduction

AEGEAN Objectives

AEGEAN Study Design

Adherence (Primary Endpoint)

Conclusion

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)